Overview

S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purposes of the study were to obtain further information about the optimal dose and the efficacy of Keppra in daily clinical practice, and to confirm the favorable safety and tolerability profiles of the drug observed during clinical development.
Phase:
Phase 4
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam